The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 20 of the 31 sources its claims cite were checked for support.
Targeting transcription factors through an IMiD independent zinc finger domain
Open accessPublished version of a preprint
Abstract
Immunomodulatory imide drugs (IMiDs) degrade specific C2H2 zinc finger degrons in transcription factors, making them effective against certain cancers. SALL4, a cancer driver, contains seven C2H2 zinc fingers in three clusters, including an IMiD degron in zinc finger cluster one (ZFC1). Surprisingly, IMiDs do not inhibit the growth of SALL4-expressing cancer cells. To overcome this limit, we focused on a non-IMiD domain, SALL4 zinc finger cluster four (ZFC4). By combining ZFC4-DNA crystal structure and an in silico docking algorithm, in conjunction with cell viability assays, we screened several chemical libraries against a potentially druggable binding pocket, leading to the discovery of SH6, a compound that selectively targets SALL4-expressing cancer cells. Mechanistic studies revealed that SH6 degrades SALL4 protein through the CUL4A/CRBN pathway, while deletion of ZFC4 abolished this activity. Moreover, SH6 treatment led to a significant 87% tumor growth inhibition of SALL4+ patient-derived xenografts and demonstrated good bioavailability in pharmacokinetic studies. In summary, these studies represent a new approach for IMiD independent drug discovery targeting C2H2 transcription factors such as SALL4 in cancer.
Overview
CoChat Summary
## TL;DR
The paper identifies SH6 as a small molecule that targets the ZFC4 zinc-finger domain of SALL4, degrading both SALL4 isoforms through the CUL4A/CRBN pathway and selectively killing SALL4-expressing cancer cells. In mouse models, SH6 reduced tumor growth by 87% in patient-derived xenografts and showed favorable pharmacokinetic and tolerability profiles.
## Key findings
- The authors solved the SALL4 ZFC4–DNA crystal structure at 2.1 Å and used this plus AlphaFold2-based modeling to find a druggable pocket shared by SALL4A and SALL4B.
- Screening 676 compounds yielded 119 with docking scores below −5.0; SH6 was selected as the lead because it showed the best overall potency/permeability profile.
- In cell assays, SH6 selectively killed SALL4-high cancer cells, with EC50 values of 0.5 μM in SNU398 and 0.21–1.30 μM in other SALL4-high lines, versus >10 μM in SALL4-low SNU387 cells and >25 μM in non-transformed THLE2/THLE3 cells.
- In a patient-derived xenograft from a 72-year-old male HCC patient, SH6 produced 87% tumor growth inhibition; mean tumor volume was 1495 ± 104.5 mm³ in controls versus 186.3 ± 16.4 mm³ with SH6.
- SH6 showed favorable drug-like properties, including 63.6% oral bioavailability, 1.67 h half-life in mice, and hERG blockade only at 22.2 μM.
## Methods
- Structural work: the team purified SALL4 ZFC4, co-crystallized it with a 12-bp DNA duplex, solved the structure by crystallography, and generated SALL4A/SALL4B models with AlphaFold2 for pocket prediction and docking.
- Screening and validation: 676 compounds from known and in-house libraries were docked to predicted sites, then tested in cell-based phenotypic screens in SALL4-high, SALL4-low, and isogenic SALL4A/SALL4B-overexpressing cell lines.
- Mechanism and in vivo studies: they used western blotting, CETSA, SPR, dual-luciferase/Nanoluc assays, mass spectrometry, xenograft mouse studies, and a PDX model to test target engagement, degradation mechanism, and antitumor activity.
## Limitations
- The paper notes that the precise mechanism of SH6 binding to SALL4 remains to be determined.
- The authors state that future clinical studies are needed to confirm effectiveness and safety in humans.
- Evident from the text: the in vivo efficacy data are from mouse xenograft and PDX models, not human trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
14 Valid · 0 Not valid · 7 Not checked · 59 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“We (Kong et al, 2021) and others (Pantier et al, 2021) independently found that the DNA binding domain of SALL4 is located in the fourth C2H2 zinc finger cluster (ZFC4) and that it prefers a consensus SALL4 DNA binding motif (Kong et al, 2021; Pantier et al, 2021).”
§ Targeting transcription factors through an IMiD independent zinc finger domain > Results > Combining crystal structure, and molecular docking to screen known and novel drug libraries for SALL4 ZFC4 targeting compounds
What the sources say
- Supportedcites Kong et al, 2021 source
The Discussion states that the fourth zinc finger cluster (ZFC4) is responsible for SALL4 DNA recognition and binding. The Results further show that deleting ZFC4 abolishes binding to the AT-rich consensus motif and that purified ZFC4 binds probes containing that motif. No page number is provided in our copy. (LLM, conf=0.94)
- Supportedcites Pantier et al, 2021 source
The Results section reports that inactivating ZFC4 drastically reduced SALL4 binding to AT-rich DNA. It concludes that ZFC4 is the primary determinant of SALL4 DNA binding. Page numbers were not supplied in the passages. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Using a combination of crystallography of the ZFC4 DNA binding regions with AlphaFold2, we predicted and demonstrated that SH6 binding to SALL4A and SALL4B differed from the previously reported thalidomide binding site (i.e., cerebelon-SALL4A interface)”
§ Targeting transcription factors through an IMiD independent zinc finger domain > Discussion
What the sources say
- Supportedcites Furihata et al, 2020 sourceExperimental — accuracy not yet measured
The Results section, “Structure of the 5HT-mediated SALL4–CRBN complex” (page not provided), locates thalidomide at the interface between SALL4 ZF2 and cereblon’s thalidomide-binding domain. The citing sentence uses this paper for that previously reported binding site; its finding that SH6 binds differently is the citing authors’ own work, not a finding attributed to this source. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites Matyskiela et al, 2020 source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We (Kong et al, 2021) and others (Pantier et al, 2021) independently found that the DNA binding domain of SALL4 is located in the fourth C2H2 zinc finger cluster (ZFC4) and that it prefers a consensus SALL4 DNA binding motif (Kong et al, 2021; Pantier et al, 2021).”
§ Targeting transcription factors through an IMiD independent zinc finger domain > Results > Combining crystal structure, and molecular docking to screen known and novel drug libraries for SALL4 ZFC4 targeting compounds
What the sources say
- Supportedcites Kong et al, 2021 source
The Results section ('SALL4 Binds DNA through an AT-Rich Motif') identifies the preferred consensus sequence as AA[A/T]TAT[T/G][A/G][T/A]. It also reports that deleting ZFC4 abolishes binding to that motif and that purified ZFC4 binds probes containing it. (LLM, conf=0.94)
- Partly supportedcites Pantier et al, 2021 sourceExperimental — accuracy not yet measured
The Results section, “SALL4 binds to short AT-rich motifs via C2H2 zinc-finger cluster 4 (ZFC4),” identifies ZFC4 as responsible for AT-rich DNA binding and reports ATATT as its most enriched motif. It also says several other AT-rich sequences have similar enrichment and concludes that ZFC4 targets a broad range of short A/T-only motifs, rather than a single consensus motif. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In summary, our study showcases the feasibility of combining crystallographic structural information of a zinc finger DNA binding transcription factor and AlphaFold2 (Jumper et al, 2021; Jumper and Hassabis, 2022), along with a phenotypic screen, to discover a targeted therapeutic molecule against the previously un-targetable oncofetal protein SALL4.”
§ Targeting transcription factors through an IMiD independent zinc finger domain > Discussion
What the sources say
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As a transcription factor, the uniqueness of SALL4 lies in the fact that it is expressed in embryonic cells, downregulated during development, absent in most adult tissues, and re-expressed in a significant fraction of almost all human adult tumors (Moein et al, 2022; Tatetsu et al, 2016).”
§ Targeting transcription factors through an IMiD independent zinc finger domain > Discussion
What the sources say
- Supportedcites Moein et al, 2022 source
The Introduction states that SALL4 is silenced in most adult tissues, while noting exceptions for germ cells and CD34+ hematopoietic stem cells. This directly supports the attributed claim that it is absent in most adult tissues. (LLM, conf=0.94)
- Supportedcites Tatetsu et al, 2016 source
The Introduction explicitly states that SALL4 is absent in most adult tissues. Section 1.2 further says that expression in adult human tissue is restricted to the testis and ovary, with CD34+ hematopoietic stem/progenitor cells noted as an exception. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
30 more claims · 2 with their cited sources checked
Create a free account to see all 80 claims and every source verdict.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 16
- The quote only partly states this claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“several strategies have been investigated to attenuate SALL4 function in cancer cells, including targeting of SALL4 NID 5 or C2H2 ZFCs 12 .”
From Tetramerisation governs SALL transcription factor function in development and disease (2025) · cites this paper as [12]
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764 · cited 4×
“…available ZFC4 crystal structure only encompasses a small region of the full-length SALL4 proteins, and there is currently no available SALL4B model in UniProt, we therefore used AlphaFold2 (Jumper et al, 2021; Jumper and Hassabis, 2022) to generate the 3D structural models of both isoforms (Fig.”
InfluentialCoot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Fast, scalable generation of high‐quality protein multiple sequence alignments using Clustal Omega
Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., Lopez, R., McWilliam, H., Remmert, M., Söding, J., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.75 · Cited by 15,355 · cited 1×
“Using sequence alignments with Clustal Omega (Sievers and Higgins, 2018; Sievers et al, 2011), we found that the amino acid sequence of ZFP91 and ZFP653 showed high similarity (sequence identity 38% and 40%, respectively) and were similar to that of SALL4 ZFC4 (Fig.”
Varadi, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., Yuan, D., Stroe, O., Wood, G., Laydon, A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1061 · Cited by 7,850
Cox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., & Mann, M. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.031591 · Cited by 5,180
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citationIntegration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,528 · cited 1×
“Datasets were integrated and scaled using XDS (Kabsch, 2010).”
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261 · cited 1×
“Next, we evaluated this model through a cell-based target engagement by SH6 using the cellular thermal shift assay (CETSA) (Jafari et al, 2014; Martinez Molina et al, 2013).”
Clustal Omega for making accurate alignments of many protein sequences
Sievers, F., & Higgins, D. G. (2018) · Protein Science · doi:10.1002/pro.3290 · Cited by 2,137
Cited by
Rahmani, S., Babajani, A., Abolhasani, M., Ghods, R., Kalantari, E., & Madjd, Z. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03681-w · Cited by 3
A non-IMiD multi-target degrader reactivates fetal hemoglobin
Liu, J., Shen, Z., Park, S., Dong, Y., Yu, N., Zeng, J., Lee, H., Pate, B., Adamia, S., Vanuytsel, K., et al. (2026) · Experimental Hematology and Oncology · doi:10.1101/2025.09.17.676148 · Cited by 4
Self-citationNeural crest induction requires SALL4-mediated BAF recruitment to lineage specific enhancers
Demurtas, M., Barnada, S. M., van Domselaar, E., Mitchell, Z. H., Deelen, L., & Trizzino, M. (2025) · Development · doi:10.1242/dev.205248 · Cited by 2
Tetramerisation governs SALL transcription factor function in development and disease
Giuliani, S., Chhatbar, K., Wear, M., Guy, J., Mathieson, T., Burdett, H., George, L., Alston, G., Spanos, C., McHugh, T., et al. (2025) · bioRxiv · doi:10.1101/2025.10.27.684836
Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications
Wen, J., Yu, J., Wen, W., & Jiang, B. (2026) · MedComm – Oncology · doi:10.1002/mog2.70058
Metadata
- Authors
- Liu, B. H., Liu, M., Radhakrishnan, S., Dai, M.-Y., Jaladanki, C. K., Gao, C., Tang, J. P., Kumari, K., Go, M. L., Vu, K. A. L., Kwon, J., Seo, H.-S., Song, K., Tian, X., Feng, L., Tan, J. L., Melkonian, A. V., Liu, Z., Wulf, G., Arthanari, H., Qi, J., Dhe-Paganon, S., Clohessy, J. G., Choong, Y. K., Sivaraman, J., Fan, H., Tenen, D. G., & Chai, L.
- Affiliations
- Cancer Science Institute of Singapore (SG)
- Brigham and Women's Hospital (US)
- Agency for Science, Technology and Research (SG)
- National University of Singapore (SG)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Shenzhen Bay Laboratory (CN)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Liu, Bee Hui
- Liu, Miao
- Jaladanki, Chaitanya Kumar
- Gao, Chong
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2025-05-14
- Volume
- 17
- Issue
- 6
- Pages
- 1393-1416
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC12163085
- OpenAlex
- W4410364266
- Semantic Scholar
- dc7f77f382f261d7b40d8efa0552a8190873f1e8
- Cited by
- 8
- References
- 47
- Citations by year
- 2026: 3 · 2025: 5
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- Ministry of Health -Singapore (STaR18nov-0002)
- Ministry of Education - Singapore
- National Research Foundation, Singapore (CIRG21nov-0009CIRG21nov-0009)
- Foundation for the National Institutes of Health (P01HL131477-01A1, P01 HL158688/HL/NHLBI NIH, P30 GM124165, S10OD021527)
- DOE | SC | Argonne National Laboratory
- Xiu Research Fund
- Linde Family Foundation
- AGA/Jenzabar Research Fund
- Breast Cancer Research Foundation BCRF (24-177)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- SALL4, C2H2 zinc finger transcription factor, protein degradation, small molecule inhibitors, patient-derived xenografts, tumor growth inhibition, pharmacokinetics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting transcription factors through an IMiD independent zinc finger domain. https://app.cochat.ai/papers/10.1038/s44321-025-00241-3
- The paper
- Liu, B. H., Liu, M., Radhakrishnan, S., Dai, M.-Y., Jaladanki, C. K., Gao, C., Tang, J. P., Kumari, K., Go, M. L., Vu, K. A. L., Kwon, J., Seo, H.-S., Song, K., Tian, X., Feng, L., Tan, J. L., Melkonian, A. V., Liu, Z., Wulf, G., . . . Chai, L. (2025). Targeting transcription factors through an IMiD independent zinc finger domain. EMBO Molecular Medicine. https://doi.org/10.1038/s44321-025-00241-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.